Abstract: A new second-generation antipsychotic for the treatment of schizophrenia has been found. Paliperidone ER (Invega ™) was approved in 2007 by Food and Drug Administration (FDA) to treat patients with schizophrenia. The formulation of Paliperidone ER by using the Alza OROS (Osmotic-controlled Release Oral-delivery System) and utilizing osmotic pressure release medication in smooth blood plasma levels. Several studies that were sponsored by Johnson and Johnson Pharmaceutical Research and Development found that all doses of paliperidone ER is effective in controlling a broad range of the symptoms of schizophrenia and personal and social functioning and generally well tolerated.
Kode Jurnal: jpkedokterangg130246